be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...

All articles

Filters:

Show search box

2015-03-25

Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Novartis drug “Jakavi” has been approved by the European Commission for the therapy of rare blood cancer, polycythemia vera. It is the first approved targeted drug for treatment of this disease and it gives hope for patients unresponsive to standard therapy with hydroxyurea.... Read more

Tags drug , cancer , eu , Novartis , targeted therapy , approval